Published Research

Key Published Findings

• A 2025 systematic review of 36 studies (1993–2024) found BPC-157 enhanced growth hormone receptor expression, promoted angiogenesis, and reduced inflammatory cytokines in preclinical musculoskeletal injury models. PMID: 40756949
• A 2025 scoping review reported BPC-157 demonstrated regenerative and cytoprotective effects in preclinical studies across muscle, tendon, ligament, and bone injury models, with no adverse effects reported in preclinical safety evaluations. PMID: 40789979
• Preclinical safety evaluation found no minimum toxic dose, no lethal dose, and no teratogenic, genotoxic, anaphylactic, or local toxic effects (Xu et al., 2020).

Note: Only three published human pilot studies exist as of 2025. Rigorous clinical trials are lacking. BPC-157 should be considered investigational.

Selected PubMed References

• "Emerging Use of BPC-157 in Orthopaedic Sports Medicine" — HSS Journal, 2025 — PubMed
• "Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing" — Curr Rev Musculoskelet Med, 2025 — PubMed
• Search all BPC-157 research — PubMed: "BPC-157"

Key Published Findings

• Thymosin Beta-4 increased re-epithelialization by 42% at 4 days and 61% at 7 days post-wounding compared to saline controls, with stimulated keratinocyte migration at concentrations as low as 10 pg (Malinda et al., 1999). PMID: 10469335
• A 2012 review described Thymosin Beta-4 as a "multi-functional regenerative peptide" with advances providing the scientific foundation for ongoing clinical trials in dermal wounds, corneal injuries, and cardiac tissue regeneration. PMID: 22074294
• Phase I and Phase II clinical trials have shown a high safety profile, anticipating that TB-4 will be safe at applied doses for broad clinical applications (Kleinman & Sosne, 2021). PMC: 8228050

Selected PubMed References

• "Thymosin beta4 accelerates wound healing" — J Invest Dermatol, 1999 — PubMed
• "Thymosin β4: a multi-functional regenerative peptide" — Expert Opin Biol Ther, 2012 — PubMed
• Search all TB-500 research — PubMed: "Thymosin Beta-4"

Key Published Findings

• A 2018 review described GHK-Cu's regenerative and protective actions including improved tissue repair in skin, lung, bone, liver, and stomach lining, plus multiple anti-cancer and anti-inflammatory activities, DNA repair, and proteasome activation. PMID: 29986520
• Gene profiling studies revealed GHK-Cu modulates a large number of human genes, suggesting it may belong to a class of epigenetic modifiers capable of broad protective and restorative actions (Pickart et al., 2012). PMC: 3359723
• A 2020 review found GHK-Cu can partially reverse cognitive impairment in aging mice by targeting anti-inflammatory and epigenetic pathways, providing rationale for further investigation in aging studies. PMID: 35083444

Selected PubMed References

• "Regenerative and Protective Actions of the GHK-Cu Peptide" — Int J Mol Sci, 2018 — PubMed
• "The Human Tripeptide GHK-Cu in Prevention of Oxidative Stress" — Oxid Med Cell Longev, 2012 — PMC
• Search all GHK-Cu research — PubMed: "GHK-Cu"

Key Published Findings

• The original 1998 characterization study found Ipamorelin released GH with potency comparable to GHRP-6 but — unlike other secretagogues — did not significantly affect ACTH or cortisol levels, even at doses 200-fold higher than the GH-releasing ED50. PMID: 9849822
• In adult rat models, Ipamorelin counteracted glucocorticoid-induced decreases in bone formation and increased maximum tetanic muscle tension, with periosteal bone formation rate increasing four-fold (Svensson et al., 2001). PMID: 11735244
• A 2020 review of growth hormone secretagogues identified Ipamorelin as a potent GH and IGF-1 stimulator that can improve body composition in preclinical models. PMC: 7108996

Selected PubMed References

• "Ipamorelin, the first selective growth hormone secretagogue" — Eur J Endocrinol, 1998 — PubMed
• "The GHS ipamorelin counteracts glucocorticoid-induced decrease in bone formation" — Growth Horm IGF Res, 2001 — PubMed
• Search all Ipamorelin research — PubMed: "Ipamorelin"

Key Published Findings

• A 2023 review described MOTS-c's role in glucose metabolism in skeletal muscle and its potential relevance to diabetes, obesity, and aging research. The protein is transferred to the nucleus during metabolic stress and directs gene expression to promote cellular balance. PMID: 36761202
• MOTS-c promoted mitochondrial homeostasis in aged mesenchymal stem cells by activating AMPK and inhibiting mTORC1, with the mitochondrial state of treated old cells becoming more similar to young cells (Kim et al., 2021). PMID: 33639272
• A 2025 study found MOTS-c levels decrease with aging in pancreatic islet cells, and MOTS-c treatment improved pancreatic islet senescence and glucose intolerance in mouse models. PMID: 40855115

Selected PubMed References

• "MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation" — Front Endocrinol, 2023 — PubMed
• "The mitochondrial-derived peptide MOTS-c promotes homeostasis in aged MSCs" — Commun Biol, 2021 — PubMed
• Search all MOTS-c research — PubMed: "MOTS-c"

Key Published Findings

• Semax stimulated BDNF expression in different areas of the rat brain in vivo, a key neurotrophic factor investigated for its role in neuroplasticity and cognitive function (Dolotov et al., 2003). PMID: 14556513
• In rat brain focal ischemia, Semax influenced the expression of genes that promote the formation and functioning of the vascular system, with multidirectional effects on NGF and BDNF gene expression (Agapova et al., 2008). PMID: 19662538
• In conditions of rat brain focal ischemia, Semax affected the expression of genes related to the immune and vascular systems (Genbank study, 2014). PMC: 3987924

Selected PubMed References

• "The heptapeptide SEMAX stimulates BDNF expression" — Dokl Biol Sci, 2003 — PubMed
• "Comparison of the temporary dynamics of NGF and BDNF gene expression under Semax action" — J Mol Neurosci, 2010 — PubMed
• Search all Semax research — PubMed: "Semax"